• london biotech banner
  • Dermatology June 24 Conference
  • Agora
MedEdge MEA MedEdge_Logo_Dark

Public Relations, Top Health Magazine and Healthcare News GCC

  • Newsletters
  • Magazines
  • Subscribe
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
      • Healthcare Journals & Publishers
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Reading: New MSD Vaccine Approved in Europe to Protect Chickens Against ARV
Share
Notification
  • london biotech banner
  • Dermatology June 24 Conference
  • Agora
MedEdge MEA
  • Magazines
  • Newsletters
  • Profiles
  • Subscribe
Search
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Have an existing account? Sign In
MedEdge MEA > Resource Hub > Health Application > Veterinary Health > New MSD Vaccine Approved in Europe to Protect Chickens Against ARV
Veterinary Health

New MSD Vaccine Approved in Europe to Protect Chickens Against ARV

ME Desk
ME Desk
Published: May 27, 2025
Share
3 Min Read
MSD
SHARE

MSD Animal Health announced that the European Commission has granted the marketing authorization for NOBILIS MULTRIVA™ REOm for use in chickens. This vaccine is approved for the active immunization of chickens for the passive immunization of the progeny of the vaccinated chickens to reduce viraemia and clinical signs of disease caused by avian reovirus (ARV) genotypes 1 and 4. Additionally, cross-protection has been established for ARV genotypes 2, 3 and 5.  

The primary dose can be administered intramuscularly in the breast or thigh regions as a single dose from 7 weeks of age onwards. As a booster, it should be administered from 8 weeks of age onwards, but no later than 3 weeks before the onset of lay. The vaccine should be given at least 4 weeks after administration of the primary vaccination. 

“Ensuring effective prevention and control of avian reovirus is crucial for successful poultry production,” stated Maxim Nakhodko, Global Poultry Business Unit Lead at MSD Animal Health. “The approval of NOBILIS MULTRIVA™ REOm represents a valuable innovation for our customers, offering protection against one of the most significant viral pathogens affecting laying and breeding chickens.” 

Simparica Trio Gains FDA Nod to Prevent Flea Tapeworm in Dogs

WhatsApp Image 2025 05 27 at 8.15.51 PM
New MSD Vaccine Approved in Europe to Protect Chickens Against ARV 3

Zoetis announced that the U.S. Food and Drug Administration (FDA) has approved a new label indication for Simparica Trio to prevent Dipylidium caninum (flea tapeworm) infections by killing Ctenocephalides felis vector fleas in treated dogs. With this approval, Simparica Trio is the only canine combination parasiticide indicated to prevent flea tapeworm infections, at the source, by killing vector fleas before transmission.

“This latest approval of a new indication for Simparica Trio – the second brand label extension in the last six months and the fourth for our parasiticide portfolio – is yet another example of how Zoetis is an industry leader in developing innovative, next-generation parasiticide products and solutions for veterinarians and pet owners,” said Jared Shriver, President, U.S. Operations at Zoetis.

“The best and easiest way to safeguard our pets from parasites is by taking preventative measures to help reduce or eliminate illness,” said Tara Bidgood, DVM, PhD, DACVCP, Vice President, Head of Veterinary Professional Services and Medical Affairs, U.S. Independent Petcare at Zoetis. “Preventing diseases like flea tapeworm infections with this latest FDA approval for Simparica Trio, helps protect our dogs’ health but also helps strengthen the unique bond dogs share with their owners.” said Tara Bidgood

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Share
Previous Article Saudi Arabia Saudi Arabia’s Medical Tourism Market Set to Triple by 2030
Next Article Jovy's story Decades After Losing an Eye Filipina Finds Relief Through Advanced Surgery

Recent Posts

  • AriBio Signs $600M Alzheimer’s Drug Deal with UAE-Based Arcera
  • African Medical Centre of Excellence (AMCE) Opens its Doors to the Public as it Seeks to Transform Healthcare in Africa
  • Dr. Thomas Rogers Named VP and CMO of Cleveland Clinic Medina Hospital
  • Gaza’s Last Hospitals at Risk: WHO Sounds Alarm on Health System Collapse
  • A Conversation with Dr. Malaika Mendonca: A Journey Through ECMO in the UAE | SWAAC ELSO
  • Dermatology expo rome
  • LifeSpin
  • Health ExpoIraq
  • Agora
Two Point Five Logo white
  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: New MSD Vaccine Approved in Europe to Protect Chickens Against ARV
Share

Published by Two Point Five Media FZCO

  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: New MSD Vaccine Approved in Europe to Protect Chickens Against ARV
Share

Follow US on Social Media

Facebook Instagram Linkedin X-twitter Youtube Whatsapp

WhatsApp us

Logo of Medede mea
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?